Insider Selling: Axon Enterprise (NASDAQ:AXON) President Sells 13,000 Shares of Stock

Axon Enterprise, Inc (NASDAQ:AXON) President Joshua Isner sold 13,000 shares of Axon Enterprise stock in a transaction on Friday, June 5th. The stock was sold at an average price of $488.45, for a total transaction of $6,349,850.00. Following the transaction, the president directly owned 169,125 shares of the company’s stock, valued at $82,609,106.25. The trade was a 7.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Axon Enterprise Trading Down 3.1%

NASDAQ AXON traded down $15.06 on Monday, hitting $471.06. 944,826 shares of the stock were exchanged, compared to its average volume of 1,098,237. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.93 and a current ratio of 2.27. The stock has a fifty day moving average price of $408.04 and a two-hundred day moving average price of $491.56. The firm has a market capitalization of $37.97 billion, a P/E ratio of 189.18, a P/E/G ratio of 8.84 and a beta of 1.45. Axon Enterprise, Inc has a 52-week low of $339.01 and a 52-week high of $885.91.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $1.61 EPS for the quarter, topping the consensus estimate of $1.60 by $0.01. The company had revenue of $807.35 million during the quarter, compared to analyst estimates of $778.91 million. Axon Enterprise had a net margin of 6.90% and a return on equity of 3.78%. Axon Enterprise’s quarterly revenue was up 33.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.47 earnings per share. Research analysts forecast that Axon Enterprise, Inc will post 1.82 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Baillie Gifford & Co. boosted its holdings in shares of Axon Enterprise by 1,198.7% in the 4th quarter. Baillie Gifford & Co. now owns 1,642,578 shares of the biotechnology company’s stock valued at $932,869,000 after buying an additional 1,516,099 shares in the last quarter. Edgewood Management LLC purchased a new position in shares of Axon Enterprise in the 4th quarter worth approximately $846,516,000. Wellington Management Group LLP grew its position in shares of Axon Enterprise by 326.9% in the 4th quarter. Wellington Management Group LLP now owns 1,539,738 shares of the biotechnology company’s stock worth $874,463,000 after buying an additional 1,179,038 shares during the last quarter. Norges Bank purchased a new position in shares of Axon Enterprise in the 4th quarter worth approximately $515,764,000. Finally, Vanguard Group Inc. grew its position in shares of Axon Enterprise by 4.2% in the 3rd quarter. Vanguard Group Inc. now owns 9,314,164 shares of the biotechnology company’s stock worth $6,684,217,000 after buying an additional 376,904 shares during the last quarter. Institutional investors own 79.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. Wall Street Zen raised Axon Enterprise from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Craig Hallum reiterated a “buy” rating and issued a $820.00 target price on shares of Axon Enterprise in a research note on Wednesday, February 25th. Zacks Research upgraded Axon Enterprise from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 19th. Piper Sandler lowered their target price on shares of Axon Enterprise from $690.00 to $674.00 and set an “overweight” rating for the company in a research note on Thursday, May 7th. Finally, The Goldman Sachs Group set a $535.00 price target on shares of Axon Enterprise in a report on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, Axon Enterprise presently has a consensus rating of “Moderate Buy” and a consensus price target of $712.75.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.